CA2474794A1 - Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih - Google Patents
Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih Download PDFInfo
- Publication number
- CA2474794A1 CA2474794A1 CA002474794A CA2474794A CA2474794A1 CA 2474794 A1 CA2474794 A1 CA 2474794A1 CA 002474794 A CA002474794 A CA 002474794A CA 2474794 A CA2474794 A CA 2474794A CA 2474794 A1 CA2474794 A1 CA 2474794A1
- Authority
- CA
- Canada
- Prior art keywords
- mycobacterium
- cancer
- adjuvant
- formulation
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000011321 prophylaxis Methods 0.000 title abstract description 11
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims abstract description 57
- 229960001005 tuberculin Drugs 0.000 claims description 28
- 230000036039 immunity Effects 0.000 claims description 20
- 239000003755 preservative agent Substances 0.000 claims description 17
- 230000002335 preservative effect Effects 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 108010046334 Urease Proteins 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 241001506930 atypical mycobacterium Species 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 5
- 239000002480 mineral oil Substances 0.000 claims 4
- 235000010446 mineral oil Nutrition 0.000 claims 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 2
- 229920003345 Elvax® Polymers 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000000020 Nitrocellulose Substances 0.000 claims 2
- 108010073443 Ribi adjuvant Proteins 0.000 claims 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 2
- 159000000013 aluminium salts Chemical class 0.000 claims 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 235000011010 calcium phosphates Nutrition 0.000 claims 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 229920001220 nitrocellulos Polymers 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 229940031439 squalene Drugs 0.000 claims 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000187644 Mycobacterium vaccae Species 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000006997 middlebrook medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000187478 Mycobacterium chelonae Species 0.000 description 2
- 241000186365 Mycobacterium fortuitum Species 0.000 description 2
- 208000036981 active tuberculosis Diseases 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101150004367 Il4i1 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000983409 Microbacterium terrae Species 0.000 description 1
- 241001036794 Microsorum maximum Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000187486 Mycobacterium flavescens Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241001509451 Mycobacterium genavense Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241001147828 Mycobacterium haemophilum Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241001147832 Mycobacterium shimoidei Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187476 Mycobacterium triviale Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000037837 multi-bacillary leprosy Diseases 0.000 description 1
- 208000015305 multibacillary leprosy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne un procédé relatif à la prophylaxie de la tuberculose chez des sujets porteurs du VIH. Aux fins de l'invention, un vaccin à base de 'Mycobacterium w' (M¿w?) se révèle utile pour assurer ladite prophylaxie.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN81MU2002 | 2002-01-29 | ||
| IN81/MUM/2002 | 2002-01-29 | ||
| PCT/IB2003/000207 WO2003063897A1 (fr) | 2002-01-29 | 2003-01-27 | Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2474794A1 true CA2474794A1 (fr) | 2003-08-07 |
Family
ID=27638225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002474794A Abandoned CA2474794A1 (fr) | 2002-01-29 | 2003-01-27 | Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1478391A1 (fr) |
| JP (1) | JP2006502090A (fr) |
| AP (1) | AP2004003109A0 (fr) |
| BR (1) | BR0307262A (fr) |
| CA (1) | CA2474794A1 (fr) |
| EA (1) | EA200400997A1 (fr) |
| GB (1) | GB2400560A (fr) |
| WO (1) | WO2003063897A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003209534A1 (en) * | 2002-03-08 | 2003-09-22 | Bakulesh Mafatlal Khamar | The method of treating tuberculosis |
| ES2231037B1 (es) | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos. |
| ES2307402B1 (es) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | Vacuna profilactica contra la tuberculosis. |
| RU2010101164A (ru) * | 2007-06-28 | 2011-08-10 | Кадила Фармасьютикалз Лтд. (In) | Модулятор митоген-активируемой протеинкиназы |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219425D0 (en) * | 1992-09-14 | 1992-10-28 | Univ London | Therapeutic agent and its use |
| GB8918206D0 (en) * | 1989-08-09 | 1989-09-20 | Nat Inst Immunology | Tuberculosis vaccine |
| KR20050008453A (ko) * | 2002-03-08 | 2005-01-21 | 바쿠레시 마파탈 카마르 | 결핵 관리에 유용한 약제학적 조성물의 제조방법 |
-
2003
- 2003-01-27 GB GB0418776A patent/GB2400560A/en not_active Withdrawn
- 2003-01-27 CA CA002474794A patent/CA2474794A1/fr not_active Abandoned
- 2003-01-27 WO PCT/IB2003/000207 patent/WO2003063897A1/fr not_active Ceased
- 2003-01-27 EP EP03701636A patent/EP1478391A1/fr not_active Withdrawn
- 2003-01-27 JP JP2003563586A patent/JP2006502090A/ja active Pending
- 2003-01-27 EA EA200400997A patent/EA200400997A1/ru unknown
- 2003-01-27 AP APAP/P/2004/003109A patent/AP2004003109A0/en unknown
- 2003-01-27 BR BRPI0307262-2A patent/BR0307262A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0307262A (pt) | 2006-12-19 |
| EP1478391A1 (fr) | 2004-11-24 |
| WO2003063897A8 (fr) | 2005-03-31 |
| GB0418776D0 (en) | 2004-09-22 |
| WO2003063897A1 (fr) | 2003-08-07 |
| EA200400997A1 (ru) | 2005-12-29 |
| AP2004003109A0 (en) | 2004-09-30 |
| GB2400560A (en) | 2004-10-20 |
| JP2006502090A (ja) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0556241B1 (fr) | Utilisation de mycobacterium vaccae pour le traitement de l'uveite | |
| Collins | The immunology of tuberculosis | |
| JP2023153868A (ja) | 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物 | |
| CA2469266C (fr) | Methode de traitement du cancer | |
| WO2003049751A1 (fr) | Procede de fabrication d'une composition pharmaceutique utile pour combattre le cancer | |
| Shepard | The first decade in experimental leprosy | |
| CA2474794A1 (fr) | Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih | |
| WO2003075824A2 (fr) | Procede de fabrication d'une composition pharmaceutique s'utilisant contre la tuberculose | |
| WO2003063896A1 (fr) | Procede de preparation d'une composition pharmaceutique pour conferer l'immunite contre la tuberculose a des individus hiv-positifs | |
| WO2010031883A1 (fr) | Agent immunothérapeutique convenant pour la prophylaxie primaire de la tuberculose | |
| WO2003075825A2 (fr) | Procede applicable au traitement de la tuberculose | |
| AU2003202725A1 (en) | Method of providing prophylaxis for tuberculosis in HIV positive individuals | |
| KR102044585B1 (ko) | 결핵의 예방에서 경구 이용을 위한 불활성화된 미코박테리아 | |
| Julián et al. | Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette–Guerin for Nonmuscle Invasive Bladder Cancer Treatment | |
| AU2002225263B2 (en) | Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection | |
| Watson et al. | Delayed hypersensitivity responses in mice and guinea pigs to Mycobacterium leprae, Mycobacterium vaccae, and Mycobacterium nonchromogenicum cytoplasmic proteins | |
| EP1368044B1 (fr) | Immunomodulateur de gestion therapeutique de l'infection/maladie de l'immunodeficience humaine (vih) | |
| US8153102B2 (en) | Process for manufacturing pharmaceutical composition comprises of Mycobacterium w in the treatment of asthma (obstructive lung disease) | |
| WO2003075827A2 (fr) | Utilisation de mycobacterium w pour le traitement de l'asthme (maladie pulmonaire obstructive) | |
| AU2002225263A1 (en) | Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection | |
| Bennedsen et al. | The BCG‐induced resistance to listeriosis | |
| Carter | Department of Microbiology and Lobund Laboratory University of Notre Dame, Notre Dame, Indiana 46556, USA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |